Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Response to G17DT in Advanced Pancreatic Cancer
NCT02098239Phase 2Completed
- Sponsor
- Cancer Advances, Inc.
- Start
- Aug 1999
- Primary completion
- Apr 2002
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, open-label trial of G17DT immunogen in pancreatic cancer (PC) (2 arms), sponsored by Cancer Advances, Inc. Primary endpoints: Pharmacodynamic (Antibody Response) and Patient Survival. Started Aug 1999; status: completed.
02
Drugs
G17DT immunogen
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02098239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098239.